Belantamab mafodotin (Blenrep): RITIRATA l'autorizzazione alla immissione in commercio in Europa

The Conditional marketing authorisation for Blenrep (indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy) has not been renewed by the European Commission.

Source: https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep